Arbutus Biopharma Corp Accumulated Other Comprehensive Income
Arbutus Biopharma Corp (ABUS) had Accumulated Other Comprehensive Income of -$48.24 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-12
- 2013-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -15.83M CAD.
- 2012-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -12.69M CAD.
CAD
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2013-12-31 | -15.83M CAD 10-K · filed 2014-03-28 |
| 2012-12-31 | -12.69M CAD 10-K · filed 2014-03-28 |
USD
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax | Accumulated Other Comprehensive Income (Loss), Net of Tax as first filed |
|---|---|---|
| 2026-06-30 | -$48.24M 10-Q · filed 2026-08-12 | |
| 2026-03-31 | -$48.20M 10-Q · filed 2026-05-13 | |
| 2025-12-31 | -$48.10M 10-Q · filed 2026-08-12 | |
| 2025-09-30 | -$48.13M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | -$48.19M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | -$48.17M 10-Q · filed 2025-05-14 | |
| 2024-12-31 | -$48.13M 10-K · filed 2026-03-23 | |
| 2024-09-30 | -$48.09M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | -$48.31M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | -$48.37M 10-Q · filed 2024-05-02 | |
| 2023-12-31 | -$48.42M 10-K · filed 2025-03-27 | |
| 2023-09-30 | -$48.88M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | -$49.47M 10-Q · filed 2023-08-03 | |
| 2023-03-31 | -$49.63M 10-Q · filed 2023-05-04 | |
| 2022-12-31 | -$50.49M 10-K · filed 2024-03-05 | |
| 2022-09-30 | -$51.00M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | -$50.10M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | -$49.41M 10-Q · filed 2022-05-05 | |
| 2021-12-31 | -$48.34M 10-K · filed 2023-03-02 | |
| 2021-09-30 | -$48.19M 10-Q · filed 2021-11-04 | |
| 2021-06-30 | -$48.20M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | -$48.17M 10-Q · filed 2021-05-05 | |
| 2020-12-31 | -$48.17M 10-K · filed 2022-03-03 | |
| 2020-09-30 | -$48.13M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | -$48.10M 10-Q · filed 2020-08-07 | |
| 2020-03-31 | -$47.98M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | -$48.23M 10-K · filed 2021-03-04 | |
| 2019-09-30 | -$48.22M 10-Q · filed 2019-11-06 | |
| 2019-06-30 | -$48.24M 10-Q · filed 2019-08-05 | |
| 2019-03-31 | -$48.19M 10-Q · filed 2019-05-06 | |
| 2018-12-31 | -$48.17M 10-K · filed 2020-03-05 | |
| 2018-09-30 | -$48.20M 10-Q · filed 2018-11-07 | |
| 2018-06-30 | -$48.19M 10-Q · filed 2018-08-03 | |
| 2018-03-31 | -$48.19M 10-Q · filed 2018-05-04 | |
| 2017-12-31 | -$48.19M 10-K · filed 2019-03-07 | |
| 2017-09-30 | -$49.78M 10-Q · filed 2017-11-02 | |
| 2017-06-30 | -$49.78M 10-Q · filed 2017-08-03 | |
| 2017-03-31 | -$49.78M 10-Q · filed 2017-05-04 | |
| 2016-12-31 | -$48.19M 10-K · filed 2018-03-16 | -$49.78M 10-K · filed 2017-03-22 |
| 2016-09-30 | -$49.78M 10-Q · filed 2016-11-03 | |
| 2016-06-30 | -$49.78M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | -$49.78M 10-Q · filed 2016-05-04 | |
| 2015-12-31 | -$49.78M 10-K · filed 2017-03-22 | |
| 2015-09-30 | -$41.59M 10-Q · filed 2015-11-05 | |
| 2015-06-30 | -$28.26M 10-Q · filed 2015-08-07 | |
| 2015-03-31 | -$31.49M 10-Q · filed 2015-05-06 | |
| 2014-12-31 | -$22.31M 10-K · filed 2016-03-09 | |
| 2014-09-30 | -$19.04M 10-Q · filed 2014-11-07 | |
| 2014-06-30 | -$14.21M 10-Q · filed 2014-08-14 | |
| 2014-03-31 | -$17.98M 10-Q · filed 2014-05-14 | |
| 2013-12-31 | -$15.82M 10-K · filed 2015-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |